TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05382364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
Study: NCT05762107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject receives Placebo by subcutaneous injection daily for 28 days
Study: NCT05103683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: antibody drug conjugate (ADC)
Study: NCT05762107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject receives Placebo by subcutaneous injection daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject receives Placebo by subcutaneous injection daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01, 7 mg
Description: Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01, 15 mg
Description: Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01, 22 mg
Description: Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
Study: NCT06655935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary Transcatheter ASD closure
Description: deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified transcatheter ASD closure
Description: deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
Study: NCT06654310

Intervention type: BEHAVIORAL
Intervention: Delivery of FCS Skills Curriculum
Description: The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery.
Study: NCT06573216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Ambulatory Blood Pressure Monitor
Description: Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
Study: NCT06662721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
Study: NCT06662500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
Study: NCT06662903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranioplasty with Titanium mesh
Description: Cranioplasty using titanium mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranioplasty with bone cement
Description: Cranioplasty using bone cement
Study: NCT06664463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arousal enhancment protocol
Description: Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
Study: NCT06664086

Intervention type: BEHAVIORAL
Intervention: economic and psychological burden
Description: measuring the economic and psychological burden of infertility

Intervention type: BEHAVIORAL
Intervention: economic and psychological burden
Description: measuring the economic and psychological burden of infertility
Study: NCT06663527

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fumigating-washing Therapy With CPD
Description: All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: fumigating-washing therapy with a placebo
Description: fumigating-washing therapy with a placebo
Study: NCT06664216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incorrect trocar placement marks.
Description: Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incorrect trocar placement marks.
Description: Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
Study: NCT06664008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI (proton pump inhibitor)
Description: It reduces stomach acid production and manage GERD symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI (proton pump inhibitor)
Description: It reduces stomach acid production and manage GERD symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI (proton pump inhibitor)
Description: It reduces stomach acid production and manage GERD symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI (proton pump inhibitor)
Description: It reduces stomach acid production and manage GERD symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
Study: NCT06663267

Intervention type: OTHER
Intervention: NOT
Description: This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.

Intervention type: OTHER
Intervention: NOT
Description: This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.

Intervention type: OTHER
Intervention: NOT
Description: This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.

Intervention type: OTHER
Intervention: NOT
Description: This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
Study: NCT06664359

Intervention type: OTHER
Intervention: Ultrasound guided injection with local anaestethic
Description: Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position.
Study: NCT04821076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention - caloric restriction
Description: Energy restriction is set to 25 kcal / kg fat-free mass

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
Study: NCT06664359

Intervention type: OTHER
Intervention: Ultrasound guided injection with local anaestethic
Description: Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position.
Study: NCT06223672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 56g of walnuts consumed each day for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simply White Diary-free chocolate bar
Description: 68g of the white chocolate style-bar each day for 7 days
Study: NCT05242965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Given ID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05304858

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
Study: NCT05654324

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle exercises
Description: Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle exercises
Description: Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
Study: NCT06618599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mid-transverse process to pleura block combined with erector spinae block
Description: The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
Study: NCT06523270

Intervention type: RADIATION
Intervention: Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)
Description: All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner
Study: NCT05911763

Intervention type: DRUG
Intervention: Efanesoctocog Alfa BIVV001
Description: Given per investigator's discretion

Intervention type: DRUG
Intervention: Efanesoctocog Alfa BIVV001
Description: Given per investigator's discretion
Study: NCT04729504

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Project BRAVE
Description: A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
Study: NCT05429112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Tip Bougie
Description: Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube with Stylet
Description: Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
Study: NCT04800822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: PF-07284892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: lorlatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: lorlatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: lorlatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: binimetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: binimetinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: encorafenib
Study: NCT03828344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUC-MSC suspension
Description: Patients will be treated at dose of 0.75×10\^6 cells/kg of body weight (Cohort 1) or 1.5×10\^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same cell suspension as BX-U001 but without cells.
Study: NCT04645732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise therapy and self-management support program
Description: See description under Arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: See description under Arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: See description under Arms
Study: NCT04809129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted vest
Description: Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
Study: NCT06005025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder message
Description: Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received.
Study: NCT06280313

Intervention type: COMBINATION_PRODUCT
Intervention: Splenectomy+Targeted therapy+ Immunotherapy
Description: Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.